US20060106221A1 - Process for the preparation of thiazolidinedione derivatives - Google Patents

Process for the preparation of thiazolidinedione derivatives Download PDF

Info

Publication number
US20060106221A1
US20060106221A1 US11/326,003 US32600306A US2006106221A1 US 20060106221 A1 US20060106221 A1 US 20060106221A1 US 32600306 A US32600306 A US 32600306A US 2006106221 A1 US2006106221 A1 US 2006106221A1
Authority
US
United States
Prior art keywords
process according
thiazolidinedione
pharmaceutically acceptable
pyridyl
catalyst
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/326,003
Inventor
Robert Giles
Norman Lewis
John Quick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10821570&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20060106221(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US10/082,995 external-priority patent/US20020120150A1/en
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Priority to US11/326,003 priority Critical patent/US20060106221A1/en
Publication of US20060106221A1 publication Critical patent/US20060106221A1/en
Priority to US11/550,506 priority patent/US7351832B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • This invention relates to a novel process and in particular to a process for preparing certain substituted thiazolidinedione derivatives.
  • European Patent Application, Publication Number 0306228 discloses certain thiazolidinedione derivatives of formula (A): or a tautomeric form thereof or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, wherein: A a represents a substituted or unsubstituted aromatic heterocyclyl group; R a represents a hydrogen atom, an alkyl group, an acyl group, an aralkyl group, wherein the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group; R b and R c each represent hydrogen or R b and R c together represent a bond; A b represents a benzene ring having in total up to five substituents; and n′ represents an integer in the range of from 2 to 6.
  • EP 0306228 also discloses a process for reducing the compounds of formula (A) wherein R b and R c together represent a bond (the ‘benzylidene thiazolidine-2,4-diones’) to the corresponding compounds of formula (A) wherein R b and R c each represent hydrogen (the ‘benzylthiazolidine-2,4-diones’).
  • the particular reduction methods disclosed in EP 0306228 are dissolving metal methods and catalytic hydrogenation methods.
  • the present invention provides a process for preparing a compound of formula (I): or a tautomeric form thereof or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, wherein: A 1 represents a substituted or unsubstituted aromatic heterocyclyl group; R 1 represents a hydrogen atom, an alkyl group, an acyl group, an aralkyl group, wherein the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group; A 2 represents a benzene ring having in total up to five substituents; and n represents an integer in the range of from 2 to 6, which process comprises catalytically reducing a compound of formula (II): wherein A 1 , R 1 , A 2 and n are as defined in relation to formula (I), characterised in that the reduction reaction is carried out using a hydrogen pressure above 20 psi, and thereafter, if required, forming a pharmaceutically
  • the reaction is carried out at a pressure in the range of from 50 to 1500 psi, such as 60 to 1500 psi, 75 to 1500 psi, 200 to 1500 psi, 70 to 1000 psi or 200 to 1000 psi, suitably 70 to 1000 psi.
  • reaction pressures include 70, 75, 80, 500 and 1000 psi.
  • a suitable hydrogenation catalyst is a noble metal catalyst, suitably a palladium catalyst.
  • Favoured catalysts are supported noble metal catalysts, such as a palladium-on-carbon catalyst, typically comprising 5% to 10% of palladium.
  • a preferred catalyst is a 10% palladium-on-carbon catalyst.
  • Catalyst loadings (expressed as w/w % of catalyst to substrate) in the reaction are typically in the range of from 5 to 100%, usually 10 to 50% and preferably 25 to 50%.
  • the reaction may be carried out using any suitable solvent such as acetic acid, or an alkanol, such as methanol or ethanol, preferably admixed with an aqueous mineral acid such as hydrochloric acid; or tetrahydrofuran, preferably admixed with an aqueous mineral acid such as hydrochloric acid.
  • acetic acid or an alkanol, such as methanol or ethanol, preferably admixed with an aqueous mineral acid such as hydrochloric acid; or tetrahydrofuran, preferably admixed with an aqueous mineral acid such as hydrochloric acid.
  • the solvent is acetic acid or aqueous acetic acid, for example a 1:2 acetic acid:water mixture.
  • the reaction is carried out at a temperature which provides a suitable rate of formation of the required product, suitably at an elevated temperature, preferably above 70° C., for example in the range of from 80° C. to 115° C.
  • the compounds of formula (I) are isolated from the reaction and subsequently purified by use of conventional isolation and purification methods such as chromatography and crystallization/recrystalliazation.
  • a most preferred value of A 1 is a 2-pyridyl group.
  • a most preferred value of A 2 is a moiety of formula:
  • a most preferred value of R 1 is a methyl group.
  • n 2
  • a most preferred value of formula (I) is 5- ⁇ 4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl ⁇ -2,4-thiazolidinedione, or a tautomeric form thereof or a salt thereof, or a solvate thereof.
  • Crystalline 5- ⁇ 4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzylidene ⁇ -2,4-thiazolidinedione is isolated from the present reaction and as such forms a further aspect of the present invention.
  • a suitable crystallization/recrystallization solvent is denatured ethanol, the crystallization is favourably effected from refluxing solvent which is allowed to cool to provide the required compound.
  • a most preferred value of formula (II) is 5- ⁇ 4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzylidene ⁇ -2,4-thiazolidinedione or a tautomeric form thereof or a salt thereof, or a solvate thereof.
  • Suitable salts are pharmaceutically acceptable salts.
  • Suitable pharmaceutically acceptable salts include metal salts, such as for example aluminium, alkali metal salts such as sodium or potassium, alkaline earth metal salts such as calcium or magnesium and ammonium or substituted ammonium salts, for example those with lower alkylamines such as triethylamine, hydroxy alkylamines such as 2-hydroxyethylamine, bis-(2-hydroxyethyl)-amine or tri-(2-hydroxyethyl)-anine, cycloalkylamines such as bicyclohexylamine, or with procaine, dibenzylpiperidine, N-benzyl-b-phenethylamine, dehydroabietylamine, N,N′-bisdehydroabietylamine, glucamine, N-methylglucamine or bases of the pyridine type such as pyridine, collidine or quinoline.
  • metal salts such as for example aluminium, alkali metal salts such as sodium or potassium, alkaline earth metal salts
  • salts provided by pharmaceutically acceptable acids including mineral acids, including salts provided by mineral acids, such as hydrobromic, hydrochloric and sulphuric acids, and organic acids, such as methanesulphonic, tartaric and maleic acids, especially tartaric and maleic acid.
  • a preferred salt is a maleate salt.
  • Suitable solvates are pharmaceutically acceptable solvates, such as hydrates.
  • reaction time (hours.) 1 (75 psi, 100% catalyst) 15-20 2 1000 psi, 100% catalyst ⁇ 2 3 1000 psi, 50% catalyst 7 4 500 psi, 100% catalyst 4 5 500 psi, 50% catalyst ca. 12

Abstract

A process for preparing a compound of formula (I):
Figure US20060106221A1-20060518-C00001
 or a tautomeric form thereof or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, wherein:
A1 represents a substituted or unsubstituted aromatic heterocyclyl group;
R1 represents a hydrogen atom, an alkyl group, an acyl group, an aralkyl group, wherein the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group;
A2 represents a benzene ring having in total up to five substituents; and n represents an integer in the range of from 2 to 6,
which process comprises catalytically reducing a compound of formula (II):
Figure US20060106221A1-20060518-C00002
wherein A1, R1, A2 and n are as defined in relation to formula (I), characterised in that the reduction reaction is carried out using a hydrogen pressure above 20 psi; and thereafter if required forming a pharmaceutically acceptable salt and/or a pharmaceutically acceptable solvate of the compound of formula (I).

Description

  • This application is a divisional of U.S. application Ser. No. 10/288,072, filed Nov. 4, 2002, which is a continuation of U.S. application Ser. No. 10/082,995, filed Feb. 26, 2002, which is a continuation of U.S. application Ser. No. 09/530,888, filed Jul. 10, 2000, which is a 371 of International Application No. PCT/EP98/06997, filed Oct. 27, 1998.
  • This invention relates to a novel process and in particular to a process for preparing certain substituted thiazolidinedione derivatives.
  • European Patent Application, Publication Number 0306228 discloses certain thiazolidinedione derivatives of formula (A):
    Figure US20060106221A1-20060518-C00003
    or a tautomeric form thereof or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, wherein:
    Aa represents a substituted or unsubstituted aromatic heterocyclyl group;
    Ra represents a hydrogen atom, an alkyl group, an acyl group, an aralkyl group, wherein the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group;
    Rb and Rc each represent hydrogen or Rb and Rc together represent a bond;
    Ab represents a benzene ring having in total up to five substituents; and
    n′ represents an integer in the range of from 2 to 6.
  • EP 0306228 also discloses a process for reducing the compounds of formula (A) wherein Rb and Rc together represent a bond (the ‘benzylidene thiazolidine-2,4-diones’) to the corresponding compounds of formula (A) wherein Rb and Rc each represent hydrogen (the ‘benzylthiazolidine-2,4-diones’). The particular reduction methods disclosed in EP 0306228 are dissolving metal methods and catalytic hydrogenation methods.
  • It has now been discovered that when the catalytic hydrogenation of the benzylidene thiazolidine-2,4-diones is carried out using an elevated pressure of hydrogen that the reaction can be effected with a surprising reduction in the catalytic loading and reaction time and, most surprisingly, produces a significant reduction in by-product formation.
  • Accordingly, the present invention provides a process for preparing a compound of formula (I):
    Figure US20060106221A1-20060518-C00004
    or a tautomeric form thereof or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, wherein:
    A1 represents a substituted or unsubstituted aromatic heterocyclyl group;
    R1 represents a hydrogen atom, an alkyl group, an acyl group, an aralkyl group, wherein the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group;
    A2 represents a benzene ring having in total up to five substituents; and
    n represents an integer in the range of from 2 to 6,
    which process comprises catalytically reducing a compound of formula (II):
    Figure US20060106221A1-20060518-C00005
    wherein A1, R1, A2 and n are as defined in relation to formula (I), characterised in that the reduction reaction is carried out using a hydrogen pressure above 20 psi, and thereafter, if required, forming a pharmaceutically acceptable salt and/or a pharmaceutically acceptable solvate of the compound of formula (I).
  • Suitably the reaction is carried out at a pressure in the range of from 50 to 1500 psi, such as 60 to 1500 psi, 75 to 1500 psi, 200 to 1500 psi, 70 to 1000 psi or 200 to 1000 psi, suitably 70 to 1000 psi.
  • Examples of reaction pressures include 70, 75, 80, 500 and 1000 psi.
  • A suitable hydrogenation catalyst is a noble metal catalyst, suitably a palladium catalyst.
  • Favoured catalysts are supported noble metal catalysts, such as a palladium-on-carbon catalyst, typically comprising 5% to 10% of palladium.
  • A preferred catalyst is a 10% palladium-on-carbon catalyst.
  • Catalyst loadings (expressed as w/w % of catalyst to substrate) in the reaction are typically in the range of from 5 to 100%, usually 10 to 50% and preferably 25 to 50%.
  • The reaction may be carried out using any suitable solvent such as acetic acid, or an alkanol, such as methanol or ethanol, preferably admixed with an aqueous mineral acid such as hydrochloric acid; or tetrahydrofuran, preferably admixed with an aqueous mineral acid such as hydrochloric acid. Preferably the solvent is acetic acid or aqueous acetic acid, for example a 1:2 acetic acid:water mixture.
  • The reaction is carried out at a temperature which provides a suitable rate of formation of the required product, suitably at an elevated temperature, preferably above 70° C., for example in the range of from 80° C. to 115° C.
  • The compounds of formula (I) are isolated from the reaction and subsequently purified by use of conventional isolation and purification methods such as chromatography and crystallization/recrystalliazation.
  • The suitable, apt, favoured and preferred values of the variables A1, A2, R1 and n in formulae (I) and (II) are as defined in relation to formula (I) of EP 0306228.
  • A most preferred value of A1 is a 2-pyridyl group.
  • A most preferred value of A2 is a moiety of formula:
    Figure US20060106221A1-20060518-C00006
  • A most preferred value of R1 is a methyl group.
  • A most preferred value of n is 2.
  • A most preferred value of formula (I) is 5-{4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl}-2,4-thiazolidinedione, or a tautomeric form thereof or a salt thereof, or a solvate thereof.
  • Crystalline 5-{4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzylidene}-2,4-thiazolidinedione is isolated from the present reaction and as such forms a further aspect of the present invention. A suitable crystallization/recrystallization solvent is denatured ethanol, the crystallization is favourably effected from refluxing solvent which is allowed to cool to provide the required compound.
  • A most preferred value of formula (II) is 5-{4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzylidene}-2,4-thiazolidinedione or a tautomeric form thereof or a salt thereof, or a solvate thereof.
  • Suitable salts are pharmaceutically acceptable salts.
  • Suitable pharmaceutically acceptable salts include metal salts, such as for example aluminium, alkali metal salts such as sodium or potassium, alkaline earth metal salts such as calcium or magnesium and ammonium or substituted ammonium salts, for example those with lower alkylamines such as triethylamine, hydroxy alkylamines such as 2-hydroxyethylamine, bis-(2-hydroxyethyl)-amine or tri-(2-hydroxyethyl)-anine, cycloalkylamines such as bicyclohexylamine, or with procaine, dibenzylpiperidine, N-benzyl-b-phenethylamine, dehydroabietylamine, N,N′-bisdehydroabietylamine, glucamine, N-methylglucamine or bases of the pyridine type such as pyridine, collidine or quinoline.
  • In addition should be mentioned those pharmaceutically acceptable salts provided by pharmaceutically acceptable acids including mineral acids, including salts provided by mineral acids, such as hydrobromic, hydrochloric and sulphuric acids, and organic acids, such as methanesulphonic, tartaric and maleic acids, especially tartaric and maleic acid. A preferred salt is a maleate salt.
  • Suitable solvates are pharmaceutically acceptable solvates, such as hydrates.
  • The compounds of formula (II) are prepared according to known methods, for example by use of the appropriate method disclosed in EP 0306228. The contents of EP 0306228 are incorporated herein by reference.
  • The following example illustrates the invention but does not limit it in any way.
    • EXAMPLE Reduction of (Z)-5-{4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzylidene}-2,4-thiazolidinedione to 5-{4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl}-2,4-thiazolidinedione
  • To a solution of (Z)-5-{[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzylidene}-2,4-thiazolidinedione (123 kg) in glacial acetic acid (1232 L) is added 10% palladium on charcoal (Johnson-Matthey type 87L, 123 kg, catalyst contains ˜50% w/w water and hence the catalyst loading was 50% w/w). The resulting mixture is hydrogenated at 70-80 p.s.i. hydrogen pressure at about 95° C. After the starting material is consumed (15-20 hours), the reaction mixture is cooled to about 65° C. and the catalyst is removed by filtration. The resulting solution is concentrated under reduced pressure to low volume and the residue is dissolved in denatured ethanol (500 L) at 60° C. The solution is heated to reflux and then cooled to ambient temperature to effect crystallisation. The product, 5-{[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl}-2,4-thiazolidinedione, is isolated by filtration, and dried in vacuo at 45° C. Typical yields are 70-80%.
  • Effect of Change of Reaction Pressure
  • The above reaction can be performed over a range of pressures resulting in a significant reduction in reaction time and catalyst loading, as shown below.
    Reaction number Conditions Reaction Time (hours.)
    1 (75 psi, 100% catalyst) 15-20
    2 1000 psi, 100% catalyst <2
    3 1000 psi, 50% catalyst 7
    4 500 psi, 100% catalyst 4
    5 500 psi, 50% catalyst ca. 12

Claims (17)

1-10. (canceled)
11. A process for preparing a compound selected from 5-{4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl}-2,4-thiazolidinedione, or a tautomeric form thereof, or a pharmaceutical acceptable salt thereof or a pharmaceutically acceptable solvate thereof, comprising
catalytically reducing 5-{4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzylidene}-2,4-thiazolidinedione, or a tautomeric form thereof, or a salt thereof, or a solvate thereof, at a temperature above 70° C. using a hydrogen pressure above 20 psi, and
thereafter optionally forming a pharmaceutically acceptable salt or a pharmaceutically acceptable solvate of 5-{4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl}-2,4-thiazolidinedione, or a tautomeric form thereof.
12. The process according to claim 11, wherein the hydrogen pressure is in the range of from 50 to 1500 psi.
13. The process according to claim 11, wherein the hydrogen pressure is in the range of from 70 to 1000 psi.
14. The process according to claim 11, wherein the hydrogen pressure is in the range of from 70 to 80 psi.
15. The process according to claim 11, wherein the catalyst is a palladium catalyst.
16. The process according to claim 15, wherein the catalyst comprises a palladium-on-carbon catalyst.
17. The process according to claim 15, wherein the catalyst comprises a 5-10% palladium-on-carbon catalyst.
18. The process according to claim 15, wherein the catalyst loading is 10 to 50 wt/wt %.
19. The process according to claim 15, wherein the catalyst loading is 25 to 50 wt/wt %.
20. The process according to claim 11, wherein the reduction is conducted at a temperature in the range of from 80° to 115° C.
21. The process according to claim 11, wherein 5-{4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzylidene}-2,4-thiazolidinedione, or a tautomeric form thereof is catalytically reduced.
22. The process according to claim 11, wherein a salt of 5-{4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzylidene}-2,4-thiazolidinedione, or a tautomeric form thereof is catalytically reduced.
23. The process according to claim 22, wherein a mineral acid salt of 5-{4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzylidene}-2,4-thiazolidinedione, or a tautomeric form thereof is catalytically reduced.
24. The process according to claim 23, wherein the mineral acid is hydrobromic acid, hydrochloric acid, or sulphuric acid.
25. The process according to claim 22, wherein an organic acid salt of 5-{4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzylidene}-2,4-thiazolidinedione, or a tautomeric form thereof is catalytically reduced.
26. The process according to claim 25, wherein the organic acid is methanesulphonic acid or tartaric acid.
US11/326,003 1997-11-04 2006-01-05 Process for the preparation of thiazolidinedione derivatives Abandoned US20060106221A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US11/326,003 US20060106221A1 (en) 1997-11-04 2006-01-05 Process for the preparation of thiazolidinedione derivatives
US11/550,506 US7351832B2 (en) 1997-11-04 2006-10-18 Process for the preparation of thiazolidinedione derivatives

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB9723295.3 1997-11-04
GBGB9723295.3A GB9723295D0 (en) 1997-11-04 1997-11-04 Novel process
PCT/EP1998/006997 WO1999023095A1 (en) 1997-11-04 1998-10-27 Process for the preparation of thiazolidinedione derivatives
US53088800A 2000-07-10 2000-07-10
US10/082,995 US20020120150A1 (en) 1997-11-04 2002-02-26 Process for the preparation of thiazolidinedione derivatives
US28807202A 2002-11-04 2002-11-04
US11/326,003 US20060106221A1 (en) 1997-11-04 2006-01-05 Process for the preparation of thiazolidinedione derivatives

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US28807202A Division 1997-11-04 2002-11-04

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/550,506 Continuation US7351832B2 (en) 1997-11-04 2006-10-18 Process for the preparation of thiazolidinedione derivatives

Publications (1)

Publication Number Publication Date
US20060106221A1 true US20060106221A1 (en) 2006-05-18

Family

ID=10821570

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/326,003 Abandoned US20060106221A1 (en) 1997-11-04 2006-01-05 Process for the preparation of thiazolidinedione derivatives
US11/550,506 Expired - Fee Related US7351832B2 (en) 1997-11-04 2006-10-18 Process for the preparation of thiazolidinedione derivatives

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/550,506 Expired - Fee Related US7351832B2 (en) 1997-11-04 2006-10-18 Process for the preparation of thiazolidinedione derivatives

Country Status (44)

Country Link
US (2) US20060106221A1 (en)
EP (2) EP1028960B1 (en)
JP (2) JP3723448B2 (en)
KR (1) KR100602551B1 (en)
CN (1) CN1160351C (en)
AP (1) AP1519A (en)
AR (1) AR016660A1 (en)
AT (1) ATE238302T1 (en)
AU (2) AU1559599A (en)
BG (1) BG64559B1 (en)
BR (1) BR9814622A (en)
CA (1) CA2309461A1 (en)
CO (1) CO5011075A1 (en)
CZ (1) CZ297209B6 (en)
DE (1) DE69813869T2 (en)
DK (1) DK1028960T3 (en)
DZ (1) DZ2637A1 (en)
EA (1) EA002722B1 (en)
EC (1) ECSP082712A (en)
ES (1) ES2197519T3 (en)
GB (1) GB9723295D0 (en)
HK (2) HK1048804A1 (en)
HR (1) HRP20000263B1 (en)
HU (1) HU224547B1 (en)
ID (1) ID24644A (en)
IL (1) IL135898A (en)
IN (1) IN192870B (en)
MA (1) MA26560A1 (en)
MY (1) MY118605A (en)
NO (1) NO315557B1 (en)
OA (1) OA11521A (en)
PE (1) PE129399A1 (en)
PL (1) PL192503B1 (en)
PT (1) PT1028960E (en)
RS (1) RS49793B (en)
SA (1) SA98190820B1 (en)
SI (1) SI1028960T1 (en)
SK (1) SK285233B6 (en)
TR (1) TR200001239T2 (en)
TW (1) TW538037B (en)
UA (1) UA56269C2 (en)
UY (1) UY25227A1 (en)
WO (1) WO1999023095A1 (en)
ZA (1) ZA9810033B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9723295D0 (en) 1997-11-04 1998-01-07 Smithkline Beecham Plc Novel process
US7091359B2 (en) 1997-11-04 2006-08-15 Smithkline Beecham Plc Process for the preparation of thiazolidinedione derivatives
HU225919B1 (en) * 1999-12-18 2007-12-28 Richter Gedeon Nyrt Thiazolidine-derivatives, process for their preparation pharmaceutical and intermediates
GB0023971D0 (en) * 2000-09-29 2000-11-15 Smithkline Beecham Plc Novel pharmaceutical
GB0023970D0 (en) * 2000-09-29 2000-11-15 Smithkline Beecham Plc Novel pharmaceutical
IL162460A0 (en) * 2001-12-20 2005-11-20 Teva Pharma Hydrogenation of precursors to thiazolidinedione antihyperglycemics
GB0307259D0 (en) * 2003-03-28 2003-05-07 Glaxo Group Ltd Process
GB2405403A (en) * 2003-08-29 2005-03-02 Cipla Ltd Rosiglitazone maleate of particular polymorphic forms and methods of preparing rosiglitazone free base
AR047541A1 (en) * 2004-02-13 2006-01-25 Sandoz Ag PHOSPHATE OF 5 - [[4- [2-METHYL-2-PYRIDINYL-AMINO-ETOXI] PHENYL] METHYL] -2,4 THYZOLIDINADION (ROSIGLITAZONE) AND ITS POLYMORPHIC FORMS
CA2566352A1 (en) * 2004-05-12 2005-11-17 Medichem S.A. Process for the preparation of rosiglitazone
CZ297266B6 (en) * 2004-09-10 2006-10-11 Zentiva, A. S. Process for preparing rosiglitazone
CZ297347B6 (en) * 2004-09-21 2006-11-15 Zentiva, A. S. Process for preparing rosiglitazone
CZ298424B6 (en) * 2005-05-24 2007-09-26 Zentiva, A. S. Crystallization process of rosiglitazone and derivatives thereof from mixed solutions
CN102727489A (en) * 2012-07-18 2012-10-17 西南大学 Application of 5- aryl (heterocycle) methylenethiazolidine-2,4-dione in preparation of PPAR (Peroxisome Proliferator Activated Receptor) agonist

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4725610A (en) * 1984-10-03 1988-02-16 Takeda Chemical Industries, Ltd. Thiazolidinedione derivatives, their production and use
US5002953A (en) * 1987-09-04 1991-03-26 Beecham Group P.L.C. Novel compounds
US5194443A (en) * 1987-09-04 1993-03-16 Beecham Group P.L.C. Compounds
US5232925A (en) * 1987-09-04 1993-08-03 Beecham Group P.L.C. Compounds
US5260445A (en) * 1987-09-04 1993-11-09 Beecham Group P.L.C. 2,4-thiazolidinediones
US5521201A (en) * 1987-09-04 1996-05-28 Beecham Group P.L.C. Method for treatment of atherosclerosis
US5726055A (en) * 1991-11-19 1998-03-10 Smithkline Beecham Plc Process for the preparation of pharmaceutically active thiazolidine compounds by a yeast reductase
US5741803A (en) * 1992-09-05 1998-04-21 Smithkline Beecham Plc Substituted thiazolidinedionle derivatives
US5910592A (en) * 1992-09-05 1999-06-08 Smithkline Beecham Plc Substituted thiazolidinedione derivatives
US6288095B1 (en) * 1987-09-04 2001-09-11 Beecham Group P.L.C. Compounds
US20020042519A1 (en) * 1997-02-18 2002-04-11 Smithkline Beecham P.L.C. Process for the preparation of substituted thiazolidinedione
US20020049240A1 (en) * 1994-12-19 2002-04-25 Beecham Group P.1.C. Novel compounds
US20020050563A1 (en) * 1991-11-19 2002-05-02 Smithkline Beecham P.L.C. Process for the preparation of pharmaceutically active thiazolidine or oxazolidine compounds by a yeast reductase

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
US4812570A (en) 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
GB9023585D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
GB9023583D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
US5585495A (en) 1991-12-20 1996-12-17 The Upjohn Company Reduction method for substituted 5-methylene-thiazolidinediones
UY24886A1 (en) 1997-02-18 2001-08-27 Smithkline Beecham Plc TIAZOLIDINDIONA
GB9723295D0 (en) 1997-11-04 1998-01-07 Smithkline Beecham Plc Novel process
US7091359B2 (en) * 1997-11-04 2006-08-15 Smithkline Beecham Plc Process for the preparation of thiazolidinedione derivatives

Patent Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4725610A (en) * 1984-10-03 1988-02-16 Takeda Chemical Industries, Ltd. Thiazolidinedione derivatives, their production and use
US5646169A (en) * 1987-09-04 1997-07-08 Beecham Group P.L.C. Compounds for treating eating disorders in which blood glucose levels are raised
US5194443A (en) * 1987-09-04 1993-03-16 Beecham Group P.L.C. Compounds
US5232925A (en) * 1987-09-04 1993-08-03 Beecham Group P.L.C. Compounds
US5260445A (en) * 1987-09-04 1993-11-09 Beecham Group P.L.C. 2,4-thiazolidinediones
US5521201A (en) * 1987-09-04 1996-05-28 Beecham Group P.L.C. Method for treatment of atherosclerosis
US5002953A (en) * 1987-09-04 1991-03-26 Beecham Group P.L.C. Novel compounds
US5756525A (en) * 1987-09-04 1998-05-26 Beecham Group Plc Compounds for treating eating disorders
US6288095B1 (en) * 1987-09-04 2001-09-11 Beecham Group P.L.C. Compounds
US6686475B2 (en) * 1988-08-30 2004-02-03 Beecham Group P.L.C. Compounds
US20020050563A1 (en) * 1991-11-19 2002-05-02 Smithkline Beecham P.L.C. Process for the preparation of pharmaceutically active thiazolidine or oxazolidine compounds by a yeast reductase
US5726055A (en) * 1991-11-19 1998-03-10 Smithkline Beecham Plc Process for the preparation of pharmaceutically active thiazolidine compounds by a yeast reductase
US20020106762A1 (en) * 1991-11-19 2002-08-08 Smith Kline Beecham Plc Process for the preparation of pharmaceutically active thiazolidine or oxazolidine compounds by a yeast reductase
US5741803A (en) * 1992-09-05 1998-04-21 Smithkline Beecham Plc Substituted thiazolidinedionle derivatives
US5910592A (en) * 1992-09-05 1999-06-08 Smithkline Beecham Plc Substituted thiazolidinedione derivatives
US20020049240A1 (en) * 1994-12-19 2002-04-25 Beecham Group P.1.C. Novel compounds
US20020042519A1 (en) * 1997-02-18 2002-04-11 Smithkline Beecham P.L.C. Process for the preparation of substituted thiazolidinedione
US6632947B2 (en) * 1997-02-18 2003-10-14 Smithkline Beecham Plc Process for the preparation of substituted thiazolidinedione

Also Published As

Publication number Publication date
YU33800A (en) 2002-10-18
KR20010031720A (en) 2001-04-16
SA98190820B1 (en) 2006-10-29
EA200000484A1 (en) 2000-10-30
AP1519A (en) 2005-12-20
CO5011075A1 (en) 2001-02-28
AU2002300593B2 (en) 2006-03-23
US20070066662A1 (en) 2007-03-22
HK1032046A1 (en) 2001-07-06
HU224547B1 (en) 2005-10-28
IL135898A (en) 2005-08-31
CA2309461A1 (en) 1999-05-14
EP1028960B1 (en) 2003-04-23
ES2197519T3 (en) 2004-01-01
TR200001239T2 (en) 2001-07-23
AU1559599A (en) 1999-05-24
JP2004339235A (en) 2004-12-02
EP1219620A1 (en) 2002-07-03
RS49793B (en) 2008-06-05
DE69813869T2 (en) 2004-01-29
ECSP082712A (en) 2008-08-29
NO20002174D0 (en) 2000-04-27
ID24644A (en) 2000-07-27
KR100602551B1 (en) 2006-07-19
CZ20001633A3 (en) 2000-10-11
DZ2637A1 (en) 2003-03-08
CN1160351C (en) 2004-08-04
CZ297209B6 (en) 2006-10-11
BR9814622A (en) 2000-10-03
BG64559B1 (en) 2005-07-29
NO315557B1 (en) 2003-09-22
HUP0100144A2 (en) 2001-08-28
PE129399A1 (en) 2000-02-24
OA11521A (en) 2004-02-09
TW538037B (en) 2003-06-21
HK1048804A1 (en) 2003-04-17
PT1028960E (en) 2003-09-30
EA002722B1 (en) 2002-08-29
CN1278818A (en) 2001-01-03
GB9723295D0 (en) 1998-01-07
EP1028960A1 (en) 2000-08-23
AU2002300593B8 (en) 2006-05-04
AP2000001808A0 (en) 2000-06-30
SI1028960T1 (en) 2003-10-31
ZA9810033B (en) 2000-05-03
IL135898A0 (en) 2001-05-20
HUP0100144A3 (en) 2002-04-29
ATE238302T1 (en) 2003-05-15
UY25227A1 (en) 1999-05-14
IN192870B (en) 2004-05-22
UA56269C2 (en) 2003-05-15
US7351832B2 (en) 2008-04-01
SK285233B6 (en) 2006-09-07
BG104505A (en) 2001-01-31
HRP20000263B1 (en) 2009-01-31
WO1999023095A1 (en) 1999-05-14
NO20002174L (en) 2000-05-30
AR016660A1 (en) 2001-07-25
HRP20000263A2 (en) 2000-12-31
PL192503B1 (en) 2006-10-31
MY118605A (en) 2004-12-31
MA26560A1 (en) 2004-12-20
JP3723448B2 (en) 2005-12-07
JP2001521937A (en) 2001-11-13
DE69813869D1 (en) 2003-05-28
SK6502000A3 (en) 2000-09-12
DK1028960T3 (en) 2003-08-11
PL340366A1 (en) 2001-01-29

Similar Documents

Publication Publication Date Title
US7351832B2 (en) Process for the preparation of thiazolidinedione derivatives
WO1992007838A1 (en) Thiazolidine dione derivatives
JP2009149616A (en) Method for preparation of substituted thiazolidindion
US7091359B2 (en) Process for the preparation of thiazolidinedione derivatives
IE60522B1 (en) Benzoxazine derivatives and processes for preparation thereof
US20090149508A1 (en) Process for the preparation of substituted phenyl ether compounds
US7511148B2 (en) Process for preparing thiazolidinediones
EP1694646B1 (en) Process for the synthesis of pioglitazone hydrogen chloride
US20050049295A1 (en) Process for the preparation of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1piperazinyl) ethyl)-6-chloro-1, 3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride) and its intermediate
US6632947B2 (en) Process for the preparation of substituted thiazolidinedione
WO1989006651A1 (en) 1h-indazole-3-acetic acids as aldose reductase inhibitors
MXPA99007656A (en) Process for the preparation of substituted thiazolidinedione

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION